Effect of an Inhaled Corticosteroid on Airway Gene Expression in Asthma

This is a 10 week, randomized, double blind, prospective study comparing the effects of inhaled fluticasone or inhaled placebo on measures of airway function, airway remodeling and airway gene expression in asthmatic subjects. Enrollment has been completed as have all study visits. We are now in the data analysis phase. The study design was as follows: Following a one-week run-in/characterization period, subjects were randomized to receive 2 puffs BID of fluticasone (250µg/puff) or matching placebo for 8 weeks. Beginning with the run-in period, subjects recordes in a daily diary their peak flow measurements twice daily, (symptoms of cough, sputum production, wheeze, dyspnea, and chest tightness. They visited the laboratory for an interval diary review and spirometry and for medication dispensing. Bronchoscopy was performed at baseline (week 1 of the run-in), and 1 week after starting the study drug Weekly telephone contact will be made during the treatment period to monitor subject well being and to ensure compliance with study medication. There was a one-week run-out to allow monitoring of subjects after discontinuation of the study drug.

Inclusion criteria

• Male and female patients with a history of asthma between the ages of 18 and 70 years.
• PC20FEV1 Methacholine ≤ 8.0 mg/mL.
• At least one of the following symptoms, beta agonist use, or FEV1 criteria:
• Asthma symptoms on at least two days per week or Beta agonist use on at least two days per week or FEV1 < 85% predicted
• Subjects must be non-smokers (patients who have never smoked or patients who have not smoked for 1 year and have a total pack-year smoking history < 15 packs).

Exclusion criteria

• History of oral or inhaled steroid use in the past 4 weeks.
• FEV1 < 60% predicted.
• Lung disease other than asthma.
• Patients with a history of a respiratory tract infection in the 4 weeks preceding the study.
• Patients who have experienced a significant exacerbation in their asthma in the 6 weeks prior to the study.
• Patients receiving hyposensitization therapy with the exception of those who are on a stable dose for the last three months.
• Patients with cardiovascular disease (active) peptic ulcer disease or diabetes mellitus.
• Females who are lactating or who are pregnant.